Mirataz 20 mg/ml - Transdermal ointment

Authorised

- Mirtazapine hemihydrate

Product identification

Medicine name:
Mirataz 20 mg/ml - Transdermal ointment

Active substance:
Mirtazapine hemihydrate

Target species:
Cat

Route of administration:
Transdermal use

Product details

Active substance and strength:
Mirtazapine hemihydrate
0.02 gram(s) / 1.00 Tube

Pharmaceutical form:
Transdermal ointment

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QN06AX11

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Available in:
Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Ireland , Italy , Netherlands , Norway , Poland , Portugal , Romania , Slovenia , Spain , Sweden

Package description:
Packaging:Tube (PE child resistant within cardboard carton), Package_size:1 tube, Content:3 g

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application - New active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Dechra Regulatory B.V

Marketing authorisation date:
10/12/2019

Manufacturing sites for batch release:
Genera Analitika d.o.o.

Responsible authority:
European Commission

Authorisation number:
This information is not available for this product.

Date of authorisation status change:
1/02/2022

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)
Published on: 25/02/2026
Download

ema-puar-mirataz-v-4733-par-en.pdf